Parkinsonian Syndrome, Parkinson's Disease
Conditions
Keywords
parkinson, diagnosis
Brief summary
This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, \[123I\]ß-CIT, in research participants with Parkinson's disease.
Detailed description
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period. After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with \[123I\]ß CIT, an investigational radioactive material that localizes in the brain. Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.
Interventions
Sponsors
Molecular NeuroImaging
National Institutes of Health (NIH)
Institute for Neurodegenerative Disorders
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least 21 years of age * Normal screening laboratory studies * At least two of the following: resting tremor, cogwheel rigidity, bradykinesia, and postural reflex impairment
Exclusion criteria
* Pregnancy * Significant medical disease including abnormalities found on screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CIT uptake: measurement of dopamine transporter density compared with the clinical severity of illness | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement of variability of strital uptake of [123I]ß-CIT when more than one scan has occurred | — |
Outcome results
None listed